Your browser doesn't support javascript.
loading
Continuous glucose monitoring in patients with post-bariatric hypoglycaemia reduces hypoglycaemia and glycaemic variability.
Cummings, Cameron; Jiang, Alex; Sheehan, Amanda; Ferraz-Bannitz, Rafael; Puleio, Alexa; Simonson, Donald C; Dreyfuss, Jonathan M; Patti, Mary Elizabeth.
Afiliação
  • Cummings C; Research Division, Joslin Diabetes Center, Boston, Massachusetts, USA.
  • Jiang A; Research Division, Joslin Diabetes Center, Boston, Massachusetts, USA.
  • Sheehan A; Research Division, Joslin Diabetes Center, Boston, Massachusetts, USA.
  • Ferraz-Bannitz R; Research Division, Joslin Diabetes Center, Boston, Massachusetts, USA.
  • Puleio A; Harvard Medical School, Boston, Massachusetts, USA.
  • Simonson DC; Research Division, Joslin Diabetes Center, Boston, Massachusetts, USA.
  • Dreyfuss JM; Harvard Medical School, Boston, Massachusetts, USA.
  • Patti ME; Division of Endocrinology, Diabetes and Hypertension, Brigham and Women's Hospital, Boston, Massachusetts, USA.
Diabetes Obes Metab ; 25(8): 2191-2202, 2023 08.
Article em En | MEDLINE | ID: mdl-37046360
ABSTRACT

AIM:

To determine whether continuous glucose monitoring (CGM) can reduce hypoglycaemia in patients with post-bariatric hypoglycaemia (PBH). MATERIALS AND

METHODS:

In an open-label, nonrandomized, pre-post design with sequential assignment, CGM data were collected in 22 individuals with PBH in two sequential phases (i) masked (no access to sensor glucose or alarms); and (ii) unmasked (access to sensor glucose and alarms for low or rapidly declining sensor glucose). Twelve participants wore the Dexcom G4 device for a total of 28 days, while 10 wore the Dexcom G6 device for a total of 20 days.

RESULTS:

Participants with PBH spent a lower percentage of time in hypoglycaemia over 24 hours with unmasked versus masked CGM (<3.3 mM/L, or <60 mg/dL median [median absolute deviation {MAD}] 0.7 [0.8]% vs. 1.4 [1.7]%, P = 0.03; <3.9 mM/L, or <70 mg/dL median [MAD] 2.9 [2.5]% vs. 4.7 [4.8]%; P = 0.04), with similar trends overnight. Sensor glucose data from the unmasked phase showed a greater percentage of time spent between 3.9 and 10 mM/L (70-180 mg/dL) (median [MAD] 94.8 [3.9]% vs. 90.8 [5.2]%; P = 0.004) and lower glycaemic variability over 24 hours (median [MAD] mean amplitude of glycaemic excursion 4.1 [0.98] vs. 4.4 [0.99] mM/L; P = 0.04). During the day, participants also spent a greater percentage of time in normoglycaemia with unmasked CGM (median [MAD] 94.2 [4.8]% vs. 90.9 [6.2]%; P = 0.005), largely due to a reduction in hyperglycaemia (>10 mM/L, or 180 mg/dL median [MAD] 1.9 [2.2]% vs. 3.9 [3.6]%; P = 0.02).

CONCLUSIONS:

Real-time CGM data and alarms are associated with reductions in low sensor glucose, elevated sensor glucose, and glycaemic variability. This suggests CGM allows patients to detect hyperglycaemic peaks and imminent hypoglycaemia, allowing dietary modification and self-treatment to reduce hypoglycaemia. The use of CGM devices may improve safety in PBH, particularly for patients with hypoglycaemia unawareness.
Assuntos
Palavras-chave

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Bariatria / Diabetes Mellitus Tipo 1 / Hipoglicemia Tipo de estudo: Diagnostic_studies / Etiology_studies Limite: Humans Idioma: En Revista: Diabetes Obes Metab Assunto da revista: ENDOCRINOLOGIA / METABOLISMO Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Bariatria / Diabetes Mellitus Tipo 1 / Hipoglicemia Tipo de estudo: Diagnostic_studies / Etiology_studies Limite: Humans Idioma: En Revista: Diabetes Obes Metab Assunto da revista: ENDOCRINOLOGIA / METABOLISMO Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos